Skip to main content

Table 3 Univariate analysis of factors contributing to an SVR in elderly patients (n = 108)

From: The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients

Risk factor

SVR (n= 54)

non SVR (n= 54)

P value

Gender (male/female)

33/21

21/33

0.021

HCV genotype, (1/2)

35/19

51/3

< 0.001

Previous IFN therapy, (yes/no)

16/38

24/30

0.163

Diabetes mellitus, (yes/no)

7/47

12/42

0.312

Hypertension, (yes/no)

22/32

25/29

0.698

Body mass index (kg/m2), mean ± SD

23.0 ± 3.0

23.7 ± 3.0

0.212

White blood cells (/mm3), mean ± SD

4948 ± 1412

4869 ± 1260

0.761

Hemoglobin (g/dL), mean ± SD

13.9 ± 1.2

13.8 ± 1.2

0.583

Platelets (× 104/mm3), mean ± SD

16.4 ± 4.2

14.2 ± 3.3

0.003

AST (IU/L), mean ± SD

69.1 ± 44.0

61.3 ± 29.2

0.280

ALT (IU/L), mean ± SD

86.9 ± 80.7

65.1 ± 43.7

0.084

AFP (ng/ml), mean ± SD

12.1 ± 19.6

19.4 ± 39.7

0.228

Fibrosis score, (F1,2/F3,4)

36/18

27/27

0.079

Serum HCV RNA (KIU/ml), mean ± SD

1290 ± 1441

1343 ± 1265

0.838

Peg-IFN does (μg/kg week), mean ± SD

1.23 ± 0.31

1.21 ± 0.30

0.494

Daily ribavirin dose (mg/kg), mean ± SD

9.68 ± 2.96

9.48 ± 2.92

0.268

80/80/80 adherence, (yes/no)

27/27

20/34

0.244

rapid virological response, (yes/no)

24/30

0/54

< 0.001

early virological response, (yes/no)

47/7

14/40

< 0.001

  1. Data are shown as absolute values or mean ± standard deviation. AST aspartate aminotransferase; ALT alanine aminotransferase; AFP alpha-fetoprotein; HCV hepatitis C virus; Peg-IFN pegylated interferon; SVR sustained virological response